{"url_path":"/sec/nmra/8-k/2026-06-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1885522/0001193125-26-270328-index.html","accession_number":"0001193125-26-270328","cik":"0001885522","ticker":"NMRA","issuer_name":"Neumora Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1885522/0001193125-26-270328-index.html","primary_entity_key":"0001885522","primary_entity_name":"Neumora Therapeutics, Inc."},"word_count":171,"has_tables":true,"body_markdown":"Item 7.01.\n\nRegulation FD Disclosure.\n\nOn June 15, 2026, the Company announced that the Phase 3 KOASTAL-2 and -3 studies of navacaprant for the treatment of major depressive disorder (“MDD”) did not achieve statistical significance on the primary or key secondary endpoints and that the Company is discontinuing development of navacaprant. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information set forth in this Item 7.01 and in the press release attached hereto as Exhibit 99.1 is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent that the Company specifically incorporates it by reference."}